Objective: To determine the fracture resistance of resin-bonded fixed partial dentures (RBFPDs) by examining the influence of framework design and abutment mobility.
Method And Materials: RBFPD frameworks were made of zirconia (Cercon Base, Degudent) or a nonprecious alloy (reference; Dentitan, Elephant Dental) and veneered with ceramic (Cercon Ceram S, Degudent). The zirconia framework design varied between a 2-retainer RBFPD with 3 different levels of tooth mobility (groups 1 to 3) and a 1-retainer cantilever version with 2 different grades of tooth mobility (groups 4 and 5). To achieve different mobility (rigid, medium, movable), the roots of the teeth were covered with a polyether material of different thicknesses. All RBFPDs were adhesively luted on prepared human teeth (Panavia 21 Ex, Kuraray). The specimens were mechanically (1.2 x 10(6); 25 N) and thermally (6,000 x 5 degrees C/55 degrees C; 2 minutes per cycle) cycled and finally loaded to failure (universal testing machine 1445, Zwick) at a speed of 1 mm/min.
Results: The fracture force of the reference RBFPD (541 N) was significantly higher than that of both cantilever RBFPDs (group 4 = 271 N, group 5 = 104 N) and one 2-retainer group with rigid abutments (group 3 = 150 N). With 2 movable abutments, the fracture force increased to 261 N (group 1) and with mixed movable/rigid teeth to 324 N (group 2). Zirconia RBFPDs showed improved survival with increased tooth mobility, but the framework design showed only a minor influence on loss rate and fracture resistance.
Conclusions: Assuming chewing forces in anterior areas between 200 and 300 N, 1- and 2-retainer zirconia RBFPDs may be suitable as minimally invasive provisional alternatives to metal-supported RBFPDs.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Drug Development.
Alzheimers Dement
December 2024
Department of Neurology and Neurological Sciences Stanford University School of Medicine, Stanford, CA, USA.
Dementia patients often received one clinical diagnosis, yet most of these cases present multiple underlying pathologies. Bringing the transition from clinical-based to biological-based diagnosis holds promise with the diagnostic criteria proposed by the Alzheimer's Association (AA) Revised Criteria for Diagnosis and Staging of Alzheimer's Disease and the Neuronal Synuclein Disease Integrated Staging System (NSD-ISS). This session aims to explore the practical implications of the AA revised criteria for diagnosing and designing clinical trials in Lewy body disease (LBD).
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Critical Path for Alzheimer's Disease (CPAD) Consortium, Critical Path institute, Tucson, AZ, USA.
Background: To help improve the Alzheimer's disease (AD) therapeutics research and development process, the Critical Path for Alzheimer's Disease (CPAD) Consortium at the Critical Path Institute (C-Path) provides a neutral framework for the drug development industry, regulatory agencies, academia, and patient advocacy organizations to collaborate. CPAD's extensive track record of developing regulatory-grade quantitative drug development tools motivates sponsors to share patient-level data and neuroimages from clinical trials. CPAD leverages these data and uses C-Path's core competencies in data management and standardization, quantitative modeling, and regulatory science to develop tools that help de-risk decision making in AD drug development.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
In Japan, the regulatory authority approved the drug in September 2023, and on December 20, it became available for prescription country-wide under the health insurance system. However, there are strict patient, physician, and facility requirements for the prescription of Lecanemab, and various problems are anticipated in its future implementation and widespread use in society. Lecanemab is the first anti-Aβ antibody in Japan, and even dementia specialists do not have sufficient knowledge and experience in its introduction, evaluation of efficacy, and evaluation and handling of side effects.
View Article and Find Full Text PDFDrug Development.
Alzheimers Dement
December 2024
National Hospital for Neurology and Neurosurgery, University College London, London, London, United Kingdom.
Anti-amyloid therapies are ideal candidates for prevention trials. Secondary prevention in those at risk of ADAD (DIAN-TU) has shown reduction of brain amyloid deposition leads to significant downstream biological change; early secondary prevention using a monoclonal antibody in sporadic AD (AHEAD 3-45) is ongoing and will provide critical information on whether treating earlier leads to greater clinical benefit. However, this is not preventing disease but delaying onset in those with presymptomatic disease.
View Article and Find Full Text PDFDementia Care Research and Psychosocial Factors.
Alzheimers Dement
December 2024
Monash University, Melbourne, VIC, Australia.
Background: People with dementia of all ages have a human right to equal access to quality health care. Despite evidence regarding its effectiveness, many people living with dementia lack access to evidence-based rehabilitation for promoting function and quality of life. The aims of this study were to 1) explore barriers to access to dementia rehabilitation; and 2) identify solutions which improve access to rehabilitation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!